OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Orchestra BioMed Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.65+0.20 (+3.67%)
Close on Oct 19, 2026
- Market cap
- $360.54M
- P/E (TTM)
- –
- Dividend yield
- –
Orchestra BioMed Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $88.00K | $110.00K | $166.00K | $140.00K | $169.00K | $136.00K | $176.00K | $184.00K | $150.00K | $123.00K | $174.00K | $148.00K | 100.0% | -47.9% |
| Partnership revenue | – | – | $30.75M | $721.00K | $667.00K | $732.00K | $77.00K | $803.00K | $628.00K | $497.00K | $88.00K | $271.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Orchestra BioMed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.